Fortis Healthcare Delivers Strong Q2 Growth With Expanding Margins and Global Footprint
Q2 FY26 Financial Performance
Fortis Healthcare reported a robust 26% year-on-year rise in revenue for Q2FY26, backed by sustained growth across its key verticals and an increased share of complex medical procedures. The company’s international business contributed nearly 10% of overall revenues, reflecting growing foreign patient inflows.
Margins expanded during the quarter, supported by high-value cases such as oncology and bone marrow transplants. Cost rationalization initiatives and moderate price adjustments also aided profitability.
Fortis Healthcare continues to strengthen its business model around quality healthcare, operational efficiency, and a growing international presence. The company’s performance in Q2 indicates a stable trend in patient inflows, capacity utilization, and higher realization per bed.
Operational and Segmental Insights
Hospital revenues saw healthy double-digit growth, led by oncology, cardiology, and orthopedics. Complex case mix improvement and efficiency gains helped offset inflationary pressures.
The diagnostics segment also delivered a solid rebound, with margin improvement and expanding test volumes across regions. Fortis continues to focus on owned hospital assets while selectively leasing facilities like its Greater Noida unit to maintain cost balance and operational agility.
The management noted that inflation in input costs, particularly in consumables and manpower, was largely absorbed through internal efficiencies. Average price hikes during the quarter stood around 1.5%, indicating stable pricing power in core segments.
Margin Improvement and Profitability Outlook
Fortis achieved another quarter of margin expansion, driven by an improving case mix and rising contributions from international patients. The company’s EBITDA performance reflected strong cost controls and stable occupancy levels across metros and Tier-II cities.
Management remains optimistic that the structural shift toward high-value procedures and sustained focus on patient experience will ensure long-term margin stability, despite inflationary headwinds.
During the quarter, the IHH open offer was successfully closed, removing a long-standing overhang on the stock. This development is expected to enhance investor confidence and governance stability within the group structure.
Diagnostics Business Momentum
Diagnostics revenue grew steadily, supported by an 8% increase in test volumes. The company expects double-digit growth ahead as the expansion of digital diagnostic platforms and B2B channels gains traction.
Fortis is also investing in automation and advanced molecular diagnostics to strengthen profitability. Management highlighted that there remains scope for margin improvement in the diagnostics vertical as operating leverage improves in FY26.
Management reaffirmed its commitment to sustainable healthcare delivery, technological innovation, and service excellence. The focus remains on optimizing operational models while expanding geographic reach and ensuring strong patient engagement.
Key Financial Metrics Snapshot
| Metric | Q2 FY26 | YoY Change |
|---|---|---|
| Revenue | ₹1,935 Cr | +26% |
| EBITDA | ₹350 Cr | +34% |
| EBITDA Margin | 18.1% | +170 bps |
| International Business Share | 9.9% | +50 bps |
With improving fundamentals, Fortis is expected to continue its steady growth trajectory through FY26 and beyond, focusing on high-value care and strategic expansion of its healthcare delivery network.
Investor Takeaway
Fortis Healthcare’s strong quarterly numbers underline a business model focused on premium medical care and operational efficiency. With a clear roadmap for international expansion, digital transformation, and margin improvement, the company remains a compelling play in India’s healthcare growth story.
Nifty and Bank Nifty Expert Gulshan Khera, CFP®, who is a SEBI Regd Investment Adviser.
Discover more expert insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
